Estimated cost of reducing anxiety and depression in moderate to severe plaque psoriasis patients treated with guselkumab vs. adalimumab using results from the phase 3 VOYAGE 2 study

Introduction: Anxiety and depression are comorbidities associated with psoriasis. The total healthcare cost reduction associated with improvements in anxiety and depression in psoriasis patients derived from newer biologic treatments is unknown.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research